The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …

Current immune checkpoint-modulating agents have demonstrated clinical efficacy in
certain tumor types, particularly those with a high burden of tumor-specific neoantigens, high …

Highlights•Essential constituents of immunogenic cell death.•Chemotherapy-induced
modulation of antigen-presenting and immunosuppressive cells.•Clinical trials of checkpoint …

The development of immune checkpoint blockade (ICB)-based immunotherapy has
dramatically changed methods of cancer treatment. This approach triggers a durable …

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several
malignancies. While the use of single-agent or combined ICIs has achieved acceptable …

Many advances in the treatment of cancer have been driven by the development of targeted
therapies that inhibit oncogenic signaling pathways and tumor-associated angiogenesis, as …

Background Cancer immunotherapy has changed the standard of care for a subgroup of
patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown …

Recent clinical trials revealed the impressive efficacy of immunological checkpoint blockade
in different types of metastatic cancers. Such data underscore that immunotherapy is one of …

Activating the immune system to eliminate cancer cells and produce clinically relevant
responses has been a long‐standing goal of cancer research. Most promising therapeutic …

Drug development in oncology has traditionally focused on therapies that directly target
cancer cells—surgery, radiation therapy, chemotherapy, and kinase inhibitors. However, for …